Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efalizumab for Moderate to Severe Psoriasis
NCT00442650Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2004
- Primary completion
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of efalizumab in plaque psoriasis, sponsored by Merck KGaA. Started Jan 2004; status: completed.
02
Drugs
efalizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00442650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00442650.